Notice: Trying to get property 'slug' of non-object in /home/sgumdev/public_html/wp-content/themes/sgum_2016/single.php on line 44

The 12 Biotechs of Christmas: Four

By DrKSSMDPhD, December 18, 2016

(adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: "ca-pub-0585312801691043", enable_page_level_ads: true });

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.]

It’s a warm Sunday afternoon a few months from now (spring will come). You open your garage door, and are cleaning up in the yard.

You don’t notice it, but a paunchy balding old guy named Fritz from a couple of blocks over comes walking by, strolling with his wife. You heard he was once a race car driver of minor acclaim from some or another western canton of Switzerland. (What his Scandinavian wife half his age sees in him you’re not sure, but she looks bored and detached.) “How much for dat Porsche in your garage?” he hails in a German accent.

You’d practically forgotten it was there. It doesn’t even run right now, but it once ruled the roads with you at the wheel. “This old thing? Gee, how about a grand?”

Fritz pokes around, looks at the interior. “I know a guy who knows a guy….he ¬†geev you teen times dees amount. Eez right model.”

You may not realize it, but you’ve perhaps got a stock just like that in your portfolio now….you’ve given it up for dead, you’re not even counting in your totals, and you’re totally discounting what it may bring you. I’m speaking of Esperion $ESPR.

A black tomato whizzes by my right temple, a near miss. “You sold us a bill of goods with that one, Dr. KSS!” Did I now? What particular aspect of Esperion’s fortune has not come true? Where was I cardinally wrong? I admit it’s been on quite the road trip, on an excursion to $100 a share and back down to earth, and done so largely because of uncertainties, a spooked and sick biotech market and the machinations of certain charlatans at Chardan Capital. But the long thesis first presented here is intact. You’ve got to give this story arc time to complete itself. After all, upending the dogma of the most entrenched drugs of our time, statins, is no minor feat.

But that’s water under the bridge and you’re still holding. Let’s look at what’s changed since all the Esperion ...

Sign Up for a Premium Membership

To view the rest of this article (and to have full access to the rest of our articles), sign up.
Already a member, log in.

Become a member

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info